2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
102
Neoplasm Metastasis
26
Neoplasms
15
Brain Neoplasms
13
Prostatic Neoplasms
10
Endometrial Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Ovarian Neoplasms
7
Glioblastoma
7
Glioma
6
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Colorectal Neoplasms
5
Breast Diseases
5
Sarcoma
4
Recurrence
4
Pancreatic Neoplasms
4
Lymphoma, Non-Hodgkin
4
Sarcoma, Ewing
3
Osteosarcoma
3
Neoplasms by Site
3
Multiple Myeloma
3
Meningioma
3
Melanoma
3
Liposarcoma
3
Carcinoma, Renal Cell
3
Unilateral Breast Neoplasms
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Interventions
Fluorouracil
67
Radiotherapy
53
Cisplatin
52
Oxaliplatin
47
Leucovorin
37
Paclitaxel
36
Irinotecan
27
Docetaxel
23
Capecitabine
20
Nivolumab
17
Carboplatin
16
pembrolizumab
15
Radiation
15
Neoadjuvant Therapy
15
Surgical Procedures, Operative
12
Cetuximab
12
durvalumab
9
Drug Therapy
9
Biopsy
9
Taxes
8
Folfox protocol
8
Chemotherapy, Adjuvant
8
Trastuzumab
7
Magnetic Resonance Spectroscopy
7
Gefitinib
7
Endoscopy
7
tremelimumab
6
Specimen Handling
6
Endoscopy, Digestive System
6
Ramucirumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma Of Esophagus
×
abemaciclib
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled